Skip to search formSkip to main contentSkip to account menu

GED0301

Known as: mongersen 
National Institutes of Health

Related topics

Related topics

1 relation

Broader (1)

Oligonucleotides

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
Highly Cited
2019
Highly Cited
2019
Mongersen (GED-0301) for Active Crohn's Disease: Results of a Phase 3 Study.
OBJECTIVES To assess the efficacy and safety of GED-0301, an antisense oligodeoxynucleotide to Smad7, in active Crohn's disease… 
Highly Cited
2018
Highly Cited
2018
Effects of Mongersen (GED-0301) on Endoscopic and Clinical Outcomes in Patients With Active Crohn's Disease.
GED-0301 is an antisense oligodeoxynucleotide with a sequence complementary to the Smad7 mRNA transcript. Smad7 is a negative… 
2016
2016
CCL20 Is Negatively Regulated by TGF-&bgr;1 in Intestinal Epithelial Cells and Reduced in Crohn’s Disease Patients With a Successful Response to Mongersen, a Smad7 Antisense Oligonucleotide
Background and Aims The chemokine CCL20 is over-produced in epithelium of Crohn's disease [CD] patients and contributes to… 
Review
2016
Review
2016
Mongersen, an oral Smad7 antisense oligonucleotide, in patients with active Crohn’s disease
In Crohn’s disease (CD), the tissue-damaging inflammation is sustained by defects of counter-regulatory mechanisms, which… 
2016
2016
Impact of patient characteristics on the clinical efficacy of mongersen (GED‐0301), an oral Smad7 antisense oligonucleotide, in active Crohn's disease
In a phase 2 study, mongersen, an oral antisense oligonucleotide targeting Smad7, was effective in inducing clinical remission in… 
2016
2016
CCL20 Is Negatively Regulated by TGF-β1 in Intestinal Epithelial Cells and Reduced in Crohn's Disease Patients With a Successful Response to Mongersen, a Smad7 Antisense Oligonucleotide.
Review
2015
Review
2015
Antisense Approach to Inflammatory Bowel Disease: Prospects and Challenges
Despite the great success of anti-tumour necrosis factor-based therapies, the treatment of Crohn’s disease (CD) and ulcerative… 
2015
2015
Mongersen, an Oral SMAD7 Antisense Oligonucleotide, and Crohn's Disease.
Highly Cited
2012
Highly Cited
2012
A phase 1 open‐label trial shows that smad7 antisense oligonucleotide (GED0301) does not increase the risk of small bowel strictures in Crohn's disease
In Crohn's disease (CD), knockdown of Smad7, an inhibitor of Transforming Growth Factor (TGF)‐β1 activity, with a specific… 
Highly Cited
2012
Highly Cited
2012
Phase I clinical trial of Smad7 knockdown using antisense oligonucleotide in patients with active Crohn's disease.
In the gut of patients with Crohn's disease (CD), high Smad7 blocks the immune-suppressive activity of transforming growth factor… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)